Human IGF-1R/CD221 Extracellular Domain (recombinant)

• Description:

  Human IGF-1R/CD221 Extracellular Domain (recombinant)_x000D_ Catalog number: B2016808_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg_x000D_ Molecular Weight or Concentration: 81 (α subunit), 23 (β subunit), and 104 kDa (single chain)_x000D_ Supplied as: Solution_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -80°C_x000D_ Keywords: CD221, IGF-I Receptor, Insulin-like Growth Factor Receptor α- and β-chains_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Soria JC, Massard C, Lazar V, Ozoux ML, Mery-Mignard D, Deslandes A, Tolcher AW. A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours Eur J Cancer. 2013 May;49(8):1799-807._x000D_ 2: Forbes BE, Blyth AJ, Wit JM. Disorders of IGFs and IGF-1R signaling pathways Mol Cell Endocrinol. 2020 Dec 1;518:111035._x000D_ 3: Cui X, Wang F, Liu C. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy Front Immunol. 2023 Jan 19;14:1062045._x000D_ 4: Soni UK, Jenny L, Hegde RS. IGF-1R targeting in cancer - does sub-cellular localization matter? J Exp Clin Cancer Res. 2023 Oct 20;42(1):273._x000D_ 5: Ma L, Zhao W, Huang S, Xu F, Wang Y, Deng D, Zhang T, Shu S, Chen X. IGF/IGF-1R signal pathway in pain: a promising therapeutic target Int J Biol Sci. 2023 Jul 3;19(11):3472-3482._x000D_ 6: Wang P, Mak VC, Cheung LW. Drugging IGF-1R in cancer: New insights and emerging opportunities Genes Dis. 2022 Mar 23;10(1):199-211._x000D_ 7: Sun Y, Sun X, Shen B. Molecular Imaging of IGF-1R in Cancer Mol Imaging. 2017 Jan-Dec;16:1536012117736648._x000D_ 8: Tufail M, Wu C. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions Ther Deliv. 2022 Mar;13(3):167-186._x000D_ 9: Chen HX, Sharon E. IGF-1R as an anti-cancer target--trials and tribulations Chin J Cancer. 2013 May;32(5):242-52._x000D_ 10: Crudden C, Girnita A, Girnita L. Targeting the IGF-1R: The Tale of the Tortoise and the Hare Front Endocrinol (Lausanne). 2015 Apr 27;6:64. _x000D_ _x000D_ Products Related to Human IGF-1R/CD221 Extracellular Domain (recombinant) can be found at Proteins

• Short Description:

  Catalog Number: B2016808 (50 µg)_x000D_ Human IGF-1R/CD221 Extracellular Domain (recombinant) is a high quality protein that has been produced through genetic engineering techniques. In this case, the extracellular domain of the human insulin-like growth factor 1 receptor (IGF-1R), also known as CD221, has been isolated and produced in a laboratory setting. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3